Tenon Medical (TNON) investor relations material

Company overview and business model

• Medical device company focused on minimally invasive solutions for sacroiliac (SI) joint disorders causing lower back pain.

• Offers two FDA-cleared systems: Catamaran SI Joint Fusion System and SImmetry SI Joint Fusion System, targeting primary, revision, and adjunct SI joint procedures.

• Acquired assets from SiVantage, Inc. and SIMPL Medical, LLC in August 2025, expanding its product portfolio.

• Operates primarily in the US market, with ongoing clinical studies and a focus on commercial expansion.

Financial performance and metrics

• As of August 10, 2026, public float was $13.2 million, with 606,596 shares held by non-affiliates at $21.75 per share (June 22, 2026 price).

• Last reported sale price of common stock was $6.05 per share on August 10, 2026.

• Net tangible book value as of March 31, 2026, was $(3.04) per share; after the offering, as-adjusted pro forma net tangible book value would be $3.01 per share.

• Immediate dilution to new investors estimated at $3.04 per share if shares are sold at $6.05.

Use of proceeds and capital allocation

• Proceeds intended for commercial expansion, clinician training, hiring sales reps, expanding distribution, clinical research, R&D, inventory, marketing, working capital, and general corporate purposes.

• Management retains broad discretion over allocation of proceeds.